Destiny Pharma has joined a growing list of UK biotechs seeking to delist from the Alternative Investments Market (AIM) and return to private ownership. The Brighton-based company, which will put ...
UK contract development and manufacturing organization Upperton Pharma Solutions has completed the build of its new sterile ...
The UK's voluntary system for disclosing payments from pharma companies to healthcare professionals ... tip of the iceberg when it comes to drug company payments to healthcare professionals ...
Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB ...
AstraZeneca’s manufacturing will-they-won’t-they within its home country has swung back firmly toward the ‘they won’t’ camp ...
Drugmakers are growing frustrated with the National Health Service after a clawback tax unexpectedly soared, with ...
MHRA’s independence also questioned during Commons debate, with regulator accused of being too close to companies it evaluates ...
Pharma stocks have underperformed the market in the fourth quarter with the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--down 9.4% against a ...
The expansion is a natural progression for Upperton who already develops and manufactures small molecule and biological, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback